UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 
WASHINGTON, D.C. 20549 
________________ 
FORM 8-K 


CURRENT REPORT 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 

 
Date of Report (Date of earliest event reported)            October 27, 2006

 
Targeted Genetics Corporation 
(Exact name of registrant as specified in its charter)


Washington
 
0-23930
 
91-1549568
(State or other jurisdiction
of incorporation)
 
(Commission File
Number)
 
(IRS Employer
Identification No.)

1100 Olive Way, Suite 100, Seattle, Washington
 
98101
(Address of principal executive offices)
 
(Zip Code)

Registrant’s telephone number, including area code
 
(206) 623-7612
 
Not Applicable 
(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

Item 1.01. Entry into a Material Definitive Agreement. 
 
On October 27, 2006, Targeted Genetics Corporation and the Children’s Hospital of Philadelphia, or CHOP, entered into an amendment, or the Amendment, to the Agreement under an NIH Prime Award, dated February 8, 2006, between CHOP and Targeted Genetics, or the Agreement. The Agreement was previously filed as Exhibit 10.36 to Targeted Genetics’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2006.
 
Under the terms of the Amendment, the period of performance of the Agreement was extended to include the period from August 31, 2006 through August 30, 2007, or the Extended Performance Period. In addition, additional costs of $5,707,854 were authorized for Extended Performance Period and the total budget for the Extended Performance Period was capped at $8,794,877.
 
The Amendment is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits. 

(d) Exhibits:
 
 
 
10.1
 
Amendment, dated October 27, 2006, to the Agreement under an NIH Prime Award, dated February 8, 2006, between the Children’s Hospital of Philadelphia and Targeted Genetics Corporation


SIGNATURES 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
  TARGETED GENETICS CORPORATION
 
 		  
 		  
 
  By:   /s/ DAVID J. POSTON  
 
David J. Poston 
 
Vice President, Finance and Chief Financial Officer
Dated: November 1, 2006
 

 
 
INDEX TO EXHIBITS
 
 
 
 
10.1
 
Amendment, dated October 27, 2006, to the Agreement under an NIH Prime Award, dated February 8, 2006, between the Children’s Hospital of Philadelphia and Targeted Genetics Corporation